Bluebird Bio, Inc. (BLUE)
| Market Cap | 612.04M |
| Revenue (ttm) | 53.65M |
| Net Income (ttm) | -864.20M |
| Shares Out | 70.11M |
| EPS (ttm) | -12.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,251,309 |
| Open | 8.57 |
| Previous Close | 8.52 |
| Day's Range | 8.18 - 8.78 |
| 52-Week Range | 8.12 - 33.55 |
| Beta | 1.61 |
| Analysts | Hold |
| Price Target | 13.08 (+49.8%) |
| Earnings Date | Nov 3, 2021 |
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (C...
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for Bluebird Bio stock is "Hold." The 12-month stock price forecast is 13.08, which is an increase of 49.83% from the latest price.
News
Why Bluebird Bio Stock Is Sinking This Week
The biotech's latest corporate update wasn't well received by investors this week.
Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference
Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference, including 2022 program milestones and financial outlook.
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Health...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference including 2022 program milestone...
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40th Annual J.P. Morgan Healthcare Conference, Wednes...
4 Biotechs That Were Winners at ASH
Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Why Bluebird Bio Stock Is Plunging Today
The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.
Why Are Bluebird Bio Shares Trading Lower Today?
The FDA has placed a partial clinical hold on Bluebird bio Inc's (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) gene therapy program for sickle cell disease (SCD) for patients under the age of 18....
UPDATE: Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program
Bluebird Bio Inc. BLUE, +13.34% said Monday the Food and Drug Administration has placed a partial clinical hold on patients below the age of 18 in its lovo-cel sickle cell gene therapy program. The temp...
Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program
Bluebird Bio Inc. BLUE, +13.34% said Monday the Food and Drug Administration has placed a partial clinical hold on patients below the age of 18 in its lovo-cel sickle cell gene therapy program. The temp...
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell d...
Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold
The FDA has accepted for priority review Buebird bio Inc's (NASDAQ: BLUE) marketing application for elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) in patients less t...
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adr...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License App...
Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD, bb1111) gene therapy for sickle cell dis...
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Thera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (NASDAQ: BLUE) today announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlo...
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented new results for betibeglogene autotemcel (beti-cel), a deeply studied investigational gene therapy, that de...
2 Popular Healthcare Stocks I'd Avoid at All Costs
There's an entire galaxy full of better places to invest your money.
bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review
bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has granted priority review for Beti-cel, gene therapy ...
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients wi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for b...
Why Bluebird Bio Stock Plunged Today
Two analysts downgraded the biotech stock.
bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss
bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates.
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021. “This quarter was about prep...